Athira Pharma (ATHA) - Pangali EV/EBITDA

Athira Pharma, Inc. (ATHA) is a biopharmaceutical player developing drugs for nerve cell regeneration in dementia, as clearly demonstrated by the price chart on GURU.Markets, where the EV/EBITDA ratio stands at 0.00. The efficiency of discovering new formulas is enhanced here through robotic screening. The massive unmet demand of millions of patients guarantees the company colossal sales volumes upon confirmation of the therapy's efficacy.

To minimize risks when building a position, it is essential to evaluate the ratio of Enterprise Value (EV) to earnings before interest, taxes, depreciation, and amortization (EBITDA). The current EV/EBITDA multiple for Athira Pharma, Inc. (ATHA) allows for a comparison between the expansion costs of the drug phosgonimetone and the actual efficiency of assets, determining the resilience of the neuropharmaceutical scaling model to debt load.